Tyrosine Kinase Inhibitor-associated Cerebral Arterial Occlusive Disease Treated with High-flow Bypass Surgery: A Case Report
Author:
Affiliation:
1. Department of Neurosurgery, Toranomon Hospital
Publisher
Japan Neurosurgical Society
Subject
Polymers and Plastics,General Environmental Science
Link
https://www.jstage.jst.go.jp/article/nmccrj/10/0/10_2022-0298/_pdf
Reference22 articles.
1. 1) O'Hare T, Deininger MWN, Eide CA, Clackson T, Druker BJ: Targeting the BCR-ABL signaling pathway in therapy-resistant philadelphia chromosome-positive leukemia. Clin Cancer Res 17: 212-221, 2011
2. 2) Shimoni A, Volchek Y, Koren-Michowitz M, et al.: Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia: Nilotinib After SCT in CML or Ph + ALL. Cancer 121: 863-871, 2015
3. 3) Giebel S, Czyz A, Ottmann O, et al.: Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the: TKIs After AlloHSCT in Ph+ ALL. Cancer 122: 2941-2951, 2016
4. 4) Aichberger KJ, Herndlhofer S, Schernthaner GH, et al.: Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 86: 533-539, 2011
5. 5) Uemura M, Kanazawa M, Yamagishi T, et al.: Role of RNF213 p.4810K variant in the development of intracranial arterial disease in patients treated with nilotinib. J Neurol Sci 408: 116577, 2020
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Case report: Three characteristics of tyrosine kinase inhibitor-associated cerebrovascular stenosis. High threshold for infarction, atypical infarct area, and vascular recoverability under the use of ponatinib;Frontiers in Stroke;2024-04-03
2. Moyamoya disease presenting with symptomatic ischemic stroke during new-generation tyrosine kinase inhibitor treatment: two illustrative cases;Acta Neurochirurgica;2023-11-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3